Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | DHODH | Q02127 | 12/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.70 |
| ▸ | GALR3 | O60755 | 1/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20983027 | 1.00 | KMT2A (1.00) | KMT2AGAASMN1; SMN2DHODHPOLB | |
| SCHEMBL14977355 | 1.00 | KMT2A (1.00) | KMT2AGAASMN1; SMN2DHODHPOLB | |
| SCHEMBL18825168 | 0.91 | DHODH (1.00) | KMT2AGAASMN1; SMN2DHODHRAB9A | |
| SCHEMBL18825169 | 0.91 | DHODH (1.00) | KMT2AGAASMN1; SMN2DHODHRAB9A | |
| SCHEMBL18825164 | 0.91 | DHODH (1.00) | KMT2AGAASMN1; SMN2DHODHRAB9A | |
| SCHEMBL14977574 | 0.90 | KMT2A (0.82) | KMT2AGAASMN1; SMN2DHODHPOLB | |
| SCHEMBL14985304 | 0.88 | DHODH (0.81) | KMT2AGAASMN1; SMN2DHODHPOLB | |
| SCHEMBL23934837 | 0.87 | DHODH (1.00) | KMT2AGAASMN1; SMN2DHODH | |
| SCHEMBL18825207 | 0.87 | DHODH (1.00) | KMT2AGAASMN1; SMN2DHODH | |
| SCHEMBL14985273 | 0.85 | RAB9A (0.74) | KMT2AGAASMN1; SMN2DHODHPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974424-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Genase Therapeutics B.V. (NL) | 2022-03-30 | — | — | EP | claimed |
| EP-3371172-B1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B V (NL) | 2021-10-20 | — | — | EP | claimed |
| CN-108349947-B | Tetrahydroindazoles and pharmaceutical uses thereof | 格纳赛治疗有限公司 | 2021-10-01 | — | — | CN | claimed |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2021-07-29 | — | — | US | claimed |
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2021-01-12 | — | — | US | claimed |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2019-05-23 | — | — | US | claimed |
| EP-4587076-A1 | SYSTEMS AND METHODS FOR OXYGENATING BLOOD, PASSIVE OXYGENATION CIRCUITS, AND NEONATAL EXTRACORPOREAL SUPPORT SYSTEMS | The Children's Hospital Of Philadelphia (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-120028461-A | Detection method and application of blood-activating pain-relieving compound preparation | 江西百神昌诺药业有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250114464-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | UNIV ALBERTA (CA) | 2025-04-10 | — | — | US | disclosed |
| CN-119137274-A | Peptide conjugated antisense therapeutics for the treatment of diseases that modulate pre-mRNA splicing | 阿尔伯塔大学理事会 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469576-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | The Governors of the University of Alberta (CA) | 2024-12-04 | — | — | EP | disclosed |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2023-10-24 | — | — | US | disclosed |
| WO-2023141710-A1 | PRE-MRNA SLICE MODULATING PEPTIDE-CONJUGATED ANTISENSE THERAPEUTICS FOR THE TREATMENT OF DISEASES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-08-03 | — | — | WO | disclosed |
| CN-108349947-B | Tetrahydroindazoles and pharmaceutical uses thereof | 格纳赛治疗有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2021-07-29 | — | — | US | disclosed |
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | GENASE THERAPEUTICS B.V. (NL) | 2021-01-12 | — | — | US | disclosed |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | GENASE THERAPEUTICS B.V. (NL) | 2019-05-23 | — | — | US | disclosed |
| EP-3371172-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | Lain, Sonia (SE) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017077280-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | LAIN SONIA (SE) | 2017-05-11 | — | — | WO | disclosed |
| WO-2013078413-A1 | MODULATORS OF LIPID STORAGE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889564-B2 | Tetrahydroindazoles and medical uses thereof | CYP11B2, CYP11B1, CYP1A1 | KMT2A 2453/4885GAA 2741/4885SMN1; SMN2 1526/4885 |
| US-20210230141-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | CYP11B2, CYP11B1, CYP3A43 | KMT2A 2515/4885GAA 2820/4885SMN1; SMN2 1525/4885 |
| US-11795157-B2 | Tetrahydroindazoles and medical uses thereof | CYP11B2, CYP11B1, CYP3A43 | KMT2A 2515/4885GAA 2820/4885SMN1; SMN2 1525/4885 |
| US-20190152943-A1 | TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF | CYP11B2, CYP11B1, CYP1A1 | KMT2A 2453/4885GAA 2741/4885SMN1; SMN2 1526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.